AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has announced the publication of data from a multi-institutional trial of MuGard in the online edition of the journal Cancer available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full. MuGard is a mucoadhesive hydrogel. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) stock opened at $21.58 in last session, and closed at $21.35, while the day range of stock is $21.13 – $21.58. The stock showed a positive weekly performance of 6.91%.
Palatin Technologies (NYSE:PTN) major shareholder Bvf Partners L. P/Il unloaded 305,966 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. Palatin Technologies, Inc. (NYSEMKT:PTN) stock opened at $1.04, in last session and closed at $1.11, by gaining 7.77%. The 52 week range of the stock is $0.51 – $1.34. Company’s market capitalization is $43.50 million.
Atossa Genetics Inc. (NASDAQ:ATOS) is a development-stage healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions. The Company’s diagnostic tests consist of medical devices cleared by the Food and Drug Administration (FDA), which can collect fluid samples from the breast milk ducts, where over 95% of breast cancers arise. Atossa Genetics Inc (NASDAQ:ATOS) stock decreased -0.43% and finished the last session at $2.29. The EPS of the stock remained -0.65. Company’s market capitalization is $41.28 million.
Bioline, a Meridian Bioscience company Inc. (NASDAQ:VIVO) this week launched the EPIK Quantification and EPIK Amplification kits. Meridian Bioscience, Inc. (NASDAQ:VIVO) stock opened the session at $21.75, and closed the session at $21.65. The 52 week range of the stock remained $19.15 – $27.72 and the day range was $21.55 – $21.84.